Alder lands $40M in third round

With the help of Delphi Ventures and TPG Biotech, Bothell, WA-based Alder Biopharmaceuticals gained $40 million in its third round round of financing. Sevin Rosen Funds, Ventures West, H.I.G. Ventures, and WRF Capital also contributed to the round. Alder identifies, develops, and manufactures antibody therapeutics to treat autoimmune and inflammatory diseases.

"This financing will allow Alder to rapidly advance our lead antibody therapeutic ALD518 through multiple proof-of-concept trials, broaden our product pipeline, and continue to build on our proprietary antibody discovery and manufacturing technologies."

- see this release for more

ALSO: California-based ViOptix raised $12.2 million in a Series D round of financing. Report

Suggested Articles

The CTAD presentation cleared up some questions about the dataset without delivering a telling blow for either side of the debate.

Eli Lilly is combining the oncology team at Lilly Research Laboratories with Loxo Oncology and putting a trio of Loxo execs at the helm.

The failure of SAGE-217 to beat placebo wiped more than 50% off Sage’s share price as investors digested the implications of the data.